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Abstract: The adrenergic system has an important role in normal central nervous system function as 
well as in brain disease. The locus coeruleus, the main source of norepinephrine in brain, is involved in 
the regulation of learning and memory, reinforcement of sleep-wake cycle and synaptic plasticity. In 
Alzheimer’s disease, locus coeruleus degeneration is observed early in the course of the disease, years 
before the onset of clinical cognitive signs, with neurofibrillary detected at the stage of mild cognitive 
impairment, preceding amyloid deposition. Thus, in the last years, a great interest has grown in evaluating the possibility 
of central adrenergic system modulation as a therapeutic tool in Alzheimer’s disease. However, evidences do not show 
univocal results, with some studies suggesting that adrenergic stimulation might be beneficial in Alzheimer’s Disease and 
some others favoring adrenergic blockade. In this review, we summarize data from both hypothesis and describe the 
pathophysiological role of the adrenergic system in neurodegeneration.  
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INTRODUCTION 
 Alzheimer’s disease (AD) is the most common cause of 
dementia, affecting more than 20% of individuals over 80 
years of age. It is a progressive neurodegenerative disorder 
clinically characterized by memory loss, cognitive 
impairment, emotional instability and changes in personality. 
The currently available therapeutic agents are only able to 
slow disease progression, with limited benefits. Thus, there 
is an urgent need to identify new potential drug targets that 
might have an impact on the natural history of the disease. 
 Pathologically, AD is characterized by the deposition of 
extracellular β-amyloid (Aβ) plaques, intracellular 
neurofibrillary tangles of hyper-phosphorylated tau protein, 
and neuronal death in the brain. Alongside, oxidative stress, 
inflammation, reactive gliosis and blood-brain barrier 
dysfunction contribute to induce accelerated neuronal 
degeneration and synaptic dysfunction [1]. The most well 
appreciated neuronal loss is in the entorhinal cortex, 
hippocampus, and basal forebrain. However, other areas are 
affected, including locus coeruleus (LC), the major source of 
noradrenergic projections to the whole brain. 
LC AND NORADRENERGIC SYSTEM IN AD 
 The LC nucleus, situated in the pons, has been the first 
neuromodulatory system to be delineated anatomically. It is 
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connected to almost all brain regions (brainstem, cerebellum, 
diencephalon, paleo- and neocortex) with the exception of 
the basal ganglia. The LC is the unique source of 
norepinephrine (NE) in the brain, with a single neuron 
innervating different regions. The LC is part of the 
“ascending reticular activating system” and it plays an 
important role in the regulation of vigilance and sleep-wake 
cycles. Moreover, many reports have shown that LC is also 
involved in attention, synaptic plasticity, memory formation 
and retrieval, decision making and performance facilitation 
[2] (Table 1).  
 In particular, it has been shown that rats with lesions of 
the noradrenergic ascending projections show cognitive 
dysfunction. Similarly, in primates the administration of the 
α2-adrenergic receptor (α2-AR) agonist clonidine impairs 
cognitive performance by reducing NE release [2]. In human 
studies using positron emission tomography (PET) imaging, 
it has been demonstrated that during rest, clonidine 
decreased the functional strength of connections both from 
frontal cortex to thalamus and in pathways to and from 
visual cortex. Conversely, during attentional tasks, functional 
integration generally increased and a drug-induced increase 
in the modulatory effects of frontal cortex on projections 
from LC to parietal cortex was observed. These results 
suggest that noradrenergic system mediates the functional 
integration of attentional brain systems and that 
noradrenergic drugs have differential effects on brain 
processes depending on subjects' underlying arousal levels 
[3]. 
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 In addition to that, it is known that NE has a crucial role 
in synaptic plasticity in terms of promoting long-term 
potentiation (LTP) through the activation of β-AR in the 
hippocampus. Moreover, NE has been implicated in memory 
consolidation: rats experiments have shown that the 
administration of a β-AR antagonist two hours after learning 
resulted in amnesia if tested after 48 hours. However, if the 
β-AR blocker was administered immediately after learning, 
no effects were observed, suggesting a delayed role of NE in 
a late phase of long-term memory consolidation [4]. In 
addition to that, LC has been shown to take part to memory 
retrieval. In a functional MRI study in humans, subjects were 
presented with neutral faces in emotional or neutral contexts. 
The pupillary size measured during encoding was used as a 
modulator of brain responses during retrieval. Activation of 
the LC was observed during retrieval only following an 
emotional response during the encoding phase. Moreover, a 
psychophysiological interaction showed that amygdalar 
responses were more tightly related to those of the LC when 
remembering faces that had been encoded in an emotional, 
rather than neutral, context, suggesting that the coordinated 
action of the LC and the amygdala activates fronto-
hippocampal networks that are essential for memory retrieval 
[5]. 
 Moreover, NE has an important role as a vasoconstrictor, 
thus it is not surprising that this aspect has also been 
addressed in cerebral vasculature. Bekar et al., by 
manipulating cortical NE output using the selective LC 
neurotoxin N-(2-chloroethyl)-N-ethyl-2bromobenzylamine 
(dsp-4) and inhibiting LC feedback inhibition with the α2-
adrenergic antagonist atipamezole, were able to explore the 
role of NE in functional blood distribution kinetics. Indeed, 
these authors showed that the α2-adrenergic antagonist 
atipamezole results in decreased vessel diameter and that the 
NE-mediated decrease in vessel diameter improves 
synchronization both temporally and spatially in the sensory 
stimulation-mediated hyperemia with concomitant decrease 
in surrounding blood volume. These effects demonstrate that 
LC-NE enhances coupling of blood distribution changes with 
local oxygen demands and improves the ability to quickly 
redistribute blood to subsequently active brain regions, 
which is an important role for NE in optimizing 
neurovascular coupling. As LC neuron loss is prominent in 
AD, the diminished ability to couple blood volume to 
oxygen demand may contribute to their pathogenesis [6]. 
 In AD, LC degeneration is observed early in the course 
of the disease, with LC neuropathology detectable 10 years 
before clinical cognitive signs. In particular, neurofibrillary 
tangles can be detected at the stage of MCI, preceding 
amyloid deposition. Some studies have indicated that a 
significant correlation exists between LC neurodegeneration 
and AD severity and duration [7]. However, it is still argued 
whether LC is one of the initial sites of AD pathology or it 
just reflects brain insults to other connected regions. 
Moreover, despite undergoing degeneration, surviving LC 
neurons show compensatory changes aiming at preserving 
NE output, such as increased levels of mRNA for tyrosine 
hydroxylase, the rate-limiting NE biosynthetic enzyme, and 
dendrites sprouting [7].  
 Further evidence on the role of LC degeneration in AD 
comes from studies replicating selective LC insults, through 
the administration of the neurotoxin dsp-4, which induces 
LC lesions while leaving other aminergic systems intact. In 
particular, to determine the consequences of LC 
degeneration in AD, dsp-4 has been administered to 
transgenic mice that overexpress human amyloid precursor 
protein (APP). Using this model, Heneka and collaborators 
demonstrated that, 6 months after dsp-4 administration, LC 
projection areas showed a robust elevation of glial 
inflammation along with augmented amyloid plaque 
deposits. Moreover, neurodegeneration and neuronal loss 
significantly increased, together with increased memory 
deficits; micro-positron emission tomography demonstrated 
reduced cerebral glucose metabolism, disturbed neuronal 
integrity, and attenuated acetylcholinesterase activity, 
globally suggesting that LC degeneration substantially 
contributes to AD development [8]. Additional data indicate 
that dsp-4 administration in transgenic mice also induced 
changes of α1-, α2-, and β1-adreneroceptor binding sites as 
well as increased micro- and astrogliosis in cortical and 
hippocampal structures. In addition, the expression of the 
pro-inflammatory cytokines CCL2 and IL-1β were induced 
and an elevation of Aβ1-42 levels in aged dsp4-treated 
APP/presenilin 1 (PS1) mice was observed. These data 
support the hypothesis that LC degeneration leads to 
dysregulation of adrenergic receptors and exacerbation of 
Aβ-induced neuroinflammation [9]. Recently, it has been 
reported that LC degeneration might also contribute to 
olfactory deficits that have been described in the early phases 
of the disease [10]. 
Table 1. Summary of the main evidence on LC role in AD. 
• The LC is the unique source of NE in brain and it plays an important role in the regulation of vigilance and sleep-wake cycles. LC is also involved in 
attention, synaptic plasticity, memory formation and retrieval, decision making and performance facilitation 
• NE has a crucial role in synaptic plasticity in terms of promoting long-term potentiation through the activation of β-AR in the hippocampus 
• In AD, LC degeneration is observed early in the course of the disease. Some studies have indicated that a significant correlation exists between LC 
neurodegeneration and AD severity and duration 
• LC degeneration contributes to AD development	  and leads to dysregulation of adrenergic receptors and exacerbation of Aβ-induced 
neuroinflammation	  
• The addition of LC lesion on top of mutant APP expression in mice seems to recapitulate more closely the neuropathological and cognitive features 
of clinical AD 
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 In another mouse model, APP/PS1 mice were crossed 
with dopamine β-hydroxylase (DBH) knockout mice, which 
are unable to synthesize NE but otherwise have normal LC 
neurons and co-transmitters. The impairments in spatial 
memory and hippocampal long-term potentiation displayed 
by young APP/PS1 or DBH (-/-) single mutant mice were 
augmented in DBH (-/-)/APP/PS1 double mutant mice and 
were independent of Aβ accumulation [11]. Globally, these 
results suggest that the LC neuronal loss contributes to 
distinct aspects of AD; while loss of NE itself impairs 
synaptic plasticity and cognitive performance, LC neuron 
degeneration worsens AD neuropathology. Importantly, the 
addition of LC lesion on top of mutant APP expression  
in mice seems to recapitulate more closely the 
neuropathological and cognitive features of clinical AD, 
giving further credit to the role of LC and noradrenergic 
brain system in AD [7]. 
ADRENERGIC RECEPTORS IN AD 
 The effects of NE are mediated by the modulation of AR 
in brain, with both α- and β-AR playing an important role in 
brain neurotransmission. The ARs belong to the superfamily 
of the seven membrane-spanning, G-protein-coupled 
receptors (GPCR) and they are divided into two main 
groups, α and β, all highly expresses in brain, where they 
regulate synaptic transmission. In particular, β-ARs are 
distributed widely in different regions, such as the cerebral 
cortex, nucleus accumbens and striatum. At lower density, 
they are also present in amygdala, hippocampus and 
cerebellum [12]. 
 Despite responding to the same ligands (norepinephrine 
and epinephrine), ARs differ significantly in the types of 
cellular responses they mediate. Agonist binding to ARs 
catalyzes the exchange of GTP for GDP on the Gα-subunit 
of the cognate G proteins, resulting in the dissociation of the 
heterotrimer into active Gα- and Gβγ-subunits, which can 
activate independent signaling pathways. The activated Gα-
subunit dissociates from the G protein complex and 
stimulates (Gs) or inhibits (Gi) adenylyl cyclase, and 
therefore modulates the intracellular amount of cyclic AMP. 
The dissociation of the Gβγ subunit facilitates the 
juxtaposition of AR and G-protein receptor kinases (GRKs), 
which ultimately mediate the phosphorylation of AR [13]. 
GRK-mediated phosphorylation results in agonist-dependent 
desensitization (homologous desensitization) of the ARs and 
promotes the binding of the cytosolic proteins arrestins. 
Once bound to the receptor, arrestins interdict further G-
protein coupling and target the activated receptor for 
endocytosis (downregulation) [14-16]. 
 Several lines of evidence suggest that an association 
exists between AR signaling and AD. Aβ binds to β2-AR, 
and the extracellular N terminus of β2-AR is critical for the 
binding. This induces G-protein/cAMP/protein kinase A 
(PKA) signaling for glutamatergic regulation of synaptic 
activities [17]. Moreover, in brains of mice expressing 
human familial mutant presenilin 1 and amyloid precursor 
protein genes, the levels of β2-AR are drastically reduced. 
Aβ also induces internalization of β2-AR and prolonged Aβ 
treatment causes β2-AR degradation; the Aβ-induced β2-AR 
internalization requires phosphorylation of β2-AR by GRKs 
and arrestins and results in the impairment of adrenergic and 
glutamatergic activities [18]. Ligand binding studies in post-
mortem human brains have demonstrated that, compared 
with the controls, total concentrations of β-ARs are 
significantly reduced in the thalamus of AD brains. In 
particular, β1-AR concentrations are significantly reduced in 
the hippocampus, and increased in the nucleus basalis of 
Meynert and cerebellum, whereas β2-AR concentrations 
were significantly reduced in the thalamus, nucleus basalis of 
Meynert, and cerebellum and increased in the hippocampus 
and putamen of AD brains, suggesting that in patients with 
AD there are significant changes in AR subtypes in different 
brain regions [19]. Also, in lymphocytes of patients with AD 
lower β2-AR levels and lower levels ofβ2-adrenergic-
stimulated cAMP have been found, when compared to 
controls [20]. Similarly, the β-adrenergic-stimulated increase 
in cAMP was reduced approximately 80% in fibroblasts 
from Alzheimer's disease compared with age-matched 
controls [21]. Our group has previously demonstrated that 
GRK2 mRNA and protein expression in the lymphocytes of 
AD patients were higher compared to controls. Furthermore, 
lymphocyte GRK2 levels were significantly correlated to the 
degree of cognitive decline [22]. Karczewski et al. 
demonstrated the presence of agonistic autoantibodies 
directed at the α1-ARs and the β2-ARs in the circulation of 
patients with mild-to-moderate Alzheimer’s and vascular 
dementia [23]. In addition to that, it has been shown that 
patients with AD have a larger number of β1- and β2-AR in 
the hippocampus and also an increased number of β2-AR in 
cerebral microvessels [24, 25]. 
 In addition to that, genetic studies have shown a 
correlation between AR polymorphisms and AD. Yu et al. 
evaluated the association of two polymorphisms in the β2-
AR gene (Gly16Arg and Gln27Glu) with the risk of late 
onset AD in a Chinese population, demonstrating that both 
β2-AR gene variants were associated with an increased risk 
of late onset AD. Interestingly, they also showed a 
significant correlation with the apolipoprotein E ε4 allele, 
suggesting that the Gly16 and Gln27 variants are associated 
with the development of AD, and might also interact with 
apolipoprotein E ε4 status [26]. Bullido and colleagues 
analyzed the allelic frequencies of two functional single-
nucleotide polymorphisms (SNPs) in the β1-AR (ADRB1) 
and the G protein β3 subunit (GNB3) genes, in a case-
control sample of AD. They found that the GNB3 T allele 
produces a significant risk for AD in individuals 
homozygous for the ADRB1 C allele, suggesting that the 
combined effect of both polymorphisms influences AD 
susceptibility. Furthermore, the co-expression of these alleles 
in cellular models increased APP expression [27]. In a Greek 
population of sporadic AD patients, MCI cases and controls, 
a significant difference in the frequency of an ADRA2B 
genetic variation among the three groups was observed. 
Specifically, this common SNP of the ADRA2B, resulting in 
a deletion of three glutamic acids on the third intracellular 
loop of the protein, is more prevalent in controls than in AD 
and MCI patients, demonstrating a possible protective role of 
the deletion variant against the disease development [28].  
 In the light of these evidences, the idea that the 
adrenergic system might play a significant role in AD 
pathophysiology is strongly supported. However, whether 
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adrenergic stimulation or blocking can be beneficial in AD is 
still debated. In the following section we have summarized 
data from studies evaluating both hypotheses (Table 2).  
ADRENERGIC AGONISM IN AD 
 Recent studies have provided insight into the mechanisms 
linking LC degeneration, NE loss and AD pathogenesis. In 
particular, it has been demonstrated that NE is a key 
regulator of microglial function, promoting the production of 
anti-inflammatory cytokines and suppressing pro-
inflammatory molecules, such as TNF-α and IL-1β [7]. In 
this vein, LC degeneration with consequent NE deficiency 
might contribute to the initiation and progression of AD. 
Thus, studies aiming at increasing NE levels in brain with 
subsequent increased AR stimulation, have shown favorable 
effects in AD. However, recent data indicate the 
neuroprotective effects of NE might be AR-independent. 
Indeed, it has been shown that NE dose-dependently protects 
primary cortical and LC neurons from amyloid-β toxicity, 
through the activation of the tropomyosin-related kinase B 
(TrkB) and these effects not mimicked by adrenergic 
agonists [29].  
 Doze et al. have observed an enhancement in cognitive 
functions both in mice with a constitutively active mutant 
form of alpha 1a-AR and in mice treated with a selective 
alpha 1a-AR agonist (cirazoline) compared to controls, with 
improvement in synaptic plasticity, mood and also longevity 
[30]. A recent report has shown that the exposure to an 
enriched environment facilitates signaling in the 
hippocampus in mice and a key feature of the enriched 
environment effect was activation of β2 and downstream G-
protein/cAMP/protein kinase A signaling. This pathway 
prevented LTP inhibition by soluble oligomers of Aβ, which 
was also beneficially activated by prolonged oral 
administration of the β-AR agonist isoproterenol [31]. Other 
data indicate that formoterol, a long-acting β2 agonist, is 
able to improve cognitive function and restore synaptic 
plasticity in a mouse model of Down syndrome, which 
shows similar brain amyloid pathology to that observed in 
AD. Formoterol seems to act through the Fibroblast Growth 
Factor 2 (FGF2), a trophic factor synthesized by 
hippocampal cells that can enhance the proliferative activity 
of glial and neuronal precursor cells [32]. Interestingly, 
exercise is known to activate the LC and to increase brain 
norepinephrine release; based on this hypothesis, Segal et al. 
have demonstrated that both in mild cognitive impairment 
(MCI) and cognitively normal elderly individuals post-
learning, acute exercise activates the NE system, 
significantly enhancing memory in both groups and 
facilitating memory consolidation. These data suggest that 
acute exercise, activating the noradrenergic system, may 
serve as a beneficial therapeutic intervention for cognitive 
decline [33]. In addition to that, it is known thatβ3-AR are 
expressed in brain and that β3-AR agonists have been shown 
to enhance 18Fluordeoxyglucose uptake in brown adipose 
tissue in vivo. Thus, their role is of potential interest not only 
in obesity and diabetes, but also in AD. Intracranial 
Table 2. Major findings from studies evaluating the effects of adrenergic stimulation or blockade in AD. 
Authors Adrenergic modulator Major findings Reference 
Doze VA, et al. Cirazoline, agonist 
Enhancement in cognitive functions in mice, with improvement in synaptic 
plasticity, mood and also longevity 
[30] 
Li S, et al. Isoproterenol, agonist Prevented LTP inhibition by soluble oligomers of Aβ [31] 
Dang V, et al. Formoterol, agonist 
Improvement in cognitive function and restorement of synaptic plasticity in a 
mouse model of Down syndrome 
[32] 
Mirbolooki MR, et al. Mirabegron, agonist 
This β3-AR selective agonist induced a dose-dependent increase in frontal cortex 
18F-FDG uptake in rat brain 
[35] 
Scullion GA, et al. Fluparoxan, antagonist 
Chronic treatment with thisα2-AR antagonist can prevent the onset of AD-like 
pathology and memory deficits in APP/PS1 transgenic mice, reducing amyloid 
deposition and astrocytosis and preventing spatial working memory deficits  
[36] 
Dobarro M, et al. Propranolol, antagonist 
Able to attenuate cognitive impairment and to counteract the increases in 
hippocampal levels of Aβ in mice. Tau hyperphosphorylation was decreased in the 
hippocampus of propranolol-treated mice 
[40] 
Wang J, et al. Carvedilol, antagonist 
Significant attenuation of brain amyloid content and cognitive deterioration in two 
AD mouse models, significantly improved neuronal transmission 
[42] 
Wang J, et al. Nebivolol, antagonist 
Nebivolol is bioavailable in brain and results in a significant reduction of amyloid 
pathology in brain 
[43] 
Ni Y, et al. ICI-118,551, antagonist 
This β2-AR–selective antagonist ameliorates amyloid plaque pathology in mouse 
models of AD 
[45] 
Katsouri L, et al. Prazosin, antagonist 
This α1-AR antagonist was able to reduce the generation of amyloid β in 
neuroblastomacells in vitro and to prevent memory deficits in transgenic AD mice  
[48] 
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administration of β3-AR antagonists induces amnesia in 
chicks, while memory loss is rescued by β3-AR antagonists 
[34]. Mirbolooki et al. have demonstrated  
that mirabegron, a β3-adrenoceptor selective agonist that 
shows some permeability across the blood-brain barrier, 
exhibited a dose-dependent increase in frontal cortex 
18Fluorodeoxyglucose uptake in rat brain [35]. 
 Apart from direct agonist stimulation, other studies have 
focused on enhancing NE release through the administration 
of antagonist to the inhibitory α2-adrenoceptor or through 
the administration of NE transporter inhibitors. Scullion et 
al. have demonstrated that chronic treatment with the α2-
adrenoceptor antagonist fluparoxan can prevent the onset of 
AD-like pathology and memory deficits in APP/PS1 
transgenic mice. Fluparoxan was able to reduce amyloid 
deposition and astrocytosis and prevented spatial working 
memory deficits in mice [36]. 
 In a clinical placebo-controlled study in patients with 
major depressive disorder, the role of NE on memory was 
evaluated by administering clonidine, anα2-AR agonist, 
which globally suppresses the noradrenergic output. 
Clonidine impaired memory consolidation in depressed 
patients and controls, suggesting that reducing noradrenergic 
activity had a specific effect on memory consolidation in 
patients with depression and healthy controls [37]. 
 Atomoxetine, an NE transporter inhibitor approved for 
the treatment of children and adults with attention-deficit 
hyperactive disorder, has been evaluated in a trial in mild-
moderate AD patients. Despite being generally well 
tolerated, 6-month atomoxetine administration was not able 
to significantly improve cognitive function. However, the 
study did not investigate the potential neuroprotective role of 
NE pharmacotherapy [38]. 
ADRENERGIC ANTAGONISM IN AD 
 While there are evidences in favor of the adrenergic 
system stimulation in AD, there is probably an equal amount 
supporting the opposite hypothesis, i.e. adrenergic blockade 
in AD. Indeed, preclinical and clinical data have 
demonstrated that blocking AR might have beneficial effects 
in AD pathogenesis. In rat astrocytes, AR stimulation with 
NE resulted in amiloyd precursor protein overexpression, 
which was inhibited by the β-AR antagonist propranolol 
[39]. The possible efficacy of propranolol on cognition and 
AD-related markers has also been studied in transgenic 
mouse models of AD, showing that propranolol, at a lower 
dose than that used as antihypertensive, was able to attenuate 
cognitive impairment and to counteract the increases in 
hippocampal levels of Aβ in mice. Moreover, Tau hyper-
phosphorylation was also decreased in the hippocampus of 
propranolol-treated mice [40]. Recently, propranolol has also 
been shown to improve performance during cognitive 
flexibility tasks in rodents [41]. Wang et al. have 
demonstrated that chronic oral administration of carvedilol, a 
nonselective β-blocker, significantly attenuates brain 
amyloid content and cognitive deterioration in two AD 
mouse models, significantly improving neuronal 
transmission [42]. The same authors also evaluated the 
effects of nebivolol, a selective β1 adrenergic receptor 
antagonist with vasodilatory properties, on the modulation of 
amyloid neuropathology in a mouse model of AD. They 
found that nebivolol is bioavailable in brain and that three 
weeks of treatment resulted in a significant reduction of 
amyloid pathology in brain, although it failed to improve 
cognitive function [43].  
 Igbavboa et al. found a link between ApoE homeostasis 
and AR in AD, showing that stimulation of β-AR increased 
cAMP levels consequently resulting in ApoE abundance; this 
increase was abolished by β-AR selective antagonists, with 
the greatest inhibition observed with the β2-AR antagonist. 
Other data have proven further insight on the important role 
of β-AR in amyloid formation [44]. Ni and colleagues 
demonstrated that β2-AR stimulation increases Aβ 
production in vitro and amyloid plaque formation in vivo by 
enhancing γ-secretase activity. They propose that β2-AR 
associates with presenilin-1 and undergoes agonist-induced 
endocytosis. Moreover, chronic treatment with β2-AR 
agonists increased cerebral amyloid plaques formation, while 
the β2-AR–selective antagonist ICI-118,551 ameliorated 
amyloid plaque pathology in mouse models of AD, 
indicating that abnormal β2-AR activation might contribute 
to Aβ accumulation in AD pathogenesis [45]. In a model of 
acute restraint stress, the administration of the β2-AR 
selective agonist clenbuterol increased the stress-induced Aβ 
production, while the β2-AR antagonist ICI 118,551 reduced 
it [46]. Moreover, it has been demonstrated that in primary 
cortical neurons Aβ is able to bind to β2AR and induce 
receptors internalization and degradation, and pretreatment 
with β-AR antagonist timolol is able to prevent this effect 
[18]. Interestingly, it has been recently demonstrated that β2-
adrenergic receptor might mediate amyloid-induced tau 
pathology in AD. Wang et al. have shown that in the 
prefrontal cortex AD transgenic mice with human familial 
mutant genes of presenilin 1 and amyloid precursor protein, 
the deletion of β2AR gene greatly decreases the 
phosphorylation of tau at Ser-214 Ser-262 and Thr-181 as 
well as the phosphorylation of other associated kinases. In 
addition to that, the density of dendritic spines and synapses, 
which is decreased in the prefrontal cortex of PS1/APP mice, 
is ameliorated by β2AR gene deletion [47]. 
 Not only β-AR, but also α-AR manipulation might play 
an important role in AD pathophysiology. Katsouri et al. 
tested the effect of various agonists and antagonists for 
adrenergic receptors on amyloid precursor protein 
processing. They found that prazosin, an α1 antagonist, was 
able to reduce the generation of amyloid β in neuroblastoma 
cells in vitro. Moreover, treatment of transgenic AD mice 
with prazosin prevented memory deficits, induced astrocytic 
proliferation and increased the release of anti-inflammatory 
cytokines, although it was not able to influence amyloid 
plaque load [48]. 
 Further data on the potential role of adrenergic blockers 
came from clinical studies examining the association of 
cardiovascular medication use and AD incidence. Data from 
the Dementia Progression Study of the Cache County Study 
indicate that the use of statins and β-blockers was associated 
with a slower annual rate of functional decline in this AD 
population, while other cardiovascular drugs did not affect 
the functional decline [49]. Interestingly, the Honolulu-Asia 
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Aging Study, a prospective, community-based cohort study 
of Japanese American men, has demonstrated that, among 
anti-hypertensive medications, β-blockers were the only 
associated with a lower risk of developing cognitive 
impairment, even after adjusting for pulse pressure, heart 
rate, baseline and mid-life systolic blood pressure and mid-
life antihypertensive treatment [50]. However, data on 
prevention of cognitive decline and dementia with blood 
pressure lowering treatments have shown inconsistent 
results, and it is not clear yet which category of 
antihypertensive drugs is the most effective in reducing the 
risk of cognitive decline [51].  
CONCLUSION 
 In conclusion, it is well established that a correlation 
between LC neurodegeneration, impaired adrenergic 
neurotransmission and AD pathogenesis exists. LC is 
affected early in the stages of AD by the formation of 
neurofibrillary tangles and its dysfunction correlates with 
cognitive decline [7]. However, whether AR stimulation or 
inhibition might be beneficial in AD therapeutics is still 
unclear. Evidence support both hypothesis, making the 
picture not easy to delineate. This might be partly due to the 
diverse effects elicited by stimulation/blocking of different 
AR subtypes and also by the cellular subset expressing the 
specific receptor. As an example, while stimulation of β-AR 
on glial cells might reduce neuroinflammation, β-AR 
blockade on brain endothelial cells might prevent 
microvascular damage. Moreover, some of the effects of NE 
as a neurotransmitter in brain are AR-independent. This dual 
favorable and harmful effect of AR modulation in AD might 
also be related to the fact that LC degeneration is 
accompanied by compensatory sprouting which might create 
a microenvironment where NE neurotransmission is 
decreased in some regions and enhanced in others. Whatever 
is the prevalent role of AR system in AD, it is certain that 
further studies are needed, aiming at investigating both 
hypotheses comprehensively.  
LIST OF ABBREVIATIONS 
AD = Alzheimer’s Dementia 
APOE = Apolipoprotein E 
APP = Amyloid Precursor Protein 
Aβ = Amyloid Beta 
cAMP = Cyclic Adenosine MonoPhosphate 
DBH = Dopamine Beta Hydroxylase 
GPCR = G-Protein-Coupled Receptors 
GRK = G-Protein Kinase Receptors 
IL-1β = Interleukin 1 Beta 
LC = Locus Coeruleus 
LTP = Long Term Potentiation 
MCI = Mild Cognitive Impairment 
MRI = Magnetic Resonance Imaging 
NE = Norepinephrine 
PET = Positron Emission Tomography 
SNP = Single-Nucleotide Polymorphisms 
TNF = Tumor Necrosis Factor 
TrkB = Tropomyosin-Related Kinase B 
Β-AR = Beta-Adrenergic Receptor 
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